Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency ...

Mektovi (binimetinib) is a brand-name oral tablet. Doctors prescribe prescribe it with Braftovi (encorafenib) for certain skin and lung cancers in adults. As with other drugs, Mektovi can cause ...

(RTTNews) - Pfizer Inc. (PFE) Tuesday said the Food and Drug Administration accepted Supplemental New Drug Applications (sNDAs) for BRAFTOVI plus MEKTOVI for patients with metastatic non-small ...

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI ® (encorafenib ...

Pfizer Inc. announced longer-term follow-up results from the phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi (encorafenib) in combination with Mektovi ...